HHLR ADVISORS, LTD.
13F Holdings and Portfolio Analysis
Zhang Lei 2026 Q1 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
HHLR ADVISORS, LTD. Overview
HHLR ADVISORS, LTD. held 38 stocks in 2026 Q1, with total market value around $1.67B.
HHLR ADVISORS, LTD.'s top five holdings in 2026 Q1: PDD HOLDINGS INC COMMON STOCK(PDD) 25.44%, Alibaba Group Holding Limited(BABA) 18.40%, BeOne Medicines AG(ONC) 18.36%, FUTU HOLDINGS LTD(FUTU) 11.60%, Legend Biotech Corporation(LEGN) 6.47%.
- Portfolio Value
- $1.67B
- Current Holdings
- 38 stocks
- New / Increased
- 9 / 2
- Reduced / Exited
- 6 / 4
Current Holdings
| 1 | PDD HOLDINGS INC COMMON STOCKPDD | 0.43 | 25.44% | 4.17 -61.15% | $102.18 | $88.14 -13.74% | $113.43 | -6.56 | 4.00 | -$0.11B-22.29% | Reduced |
| 2 | Alibaba Group Holding LimitedBABA | 0.31 | 18.40% | 2.45 -54.82% | $125.46 | $125.39 -0.06% | $146.39 | -2.98 | 4.00 | -$0.05B-14.34% | Reduced |
| 3 | BeOne Medicines AGONC | 0.31 | 18.36% | 1.03 - | $296.97 | $316.42 +6.55% | $136.90 | 0.00 | 7.50 | +$0.19B+131.14% | Held |
| 4 | FUTU HOLDINGS LTDFUTU | 0.19 | 11.60% | 1.42 -12.93% | $136.76 | $103.30 -24.47% | $95.40 | -0.21 | 2.00 | +$0.01B+8.28% | Reduced |
| 5 | Legend Biotech CorporationLEGN | 0.11 | 6.47% | 5.98 - | $18.09 | $31.96 +76.67% | $67.42 | 0.00 | 6.00 | -$0.21B-52.59% | Held |
| 6 | ArriVent BioPharma, Inc.AVBP | 0.09 | 5.42% | 3.93 - | $23.07 | $19.51 -15.43% | $17.95 | 0.00 | 2.25 | +$0.01B+8.72% | Held |
| 7 | KE Holdings Inc.BEKE | 0.06 | 3.79% | 4.24 - | $14.97 | $18.29 +22.18% | $34.89 | 0.00 | 5.75 | -$0.07B-47.57% | Held |
| 8 | Clearwater Analytics Holdings, Inc.CWAN | 0.03 | 1.93% | 1.37 - | $23.65 | $17.96 -24.06% | $21.93 | 0.00 | 1.00 | -$0.01B-18.10% | Held |
| 9 | Cytek Biosciences, Inc.CTKB | 0.03 | 1.74% | 6.66 - | $4.37 | $3.95 -9.61% | $21.41 | 0.00 | 4.75 | -$0.12B-81.55% | Held |
| 10 | Marvell Technology, Inc.MRVL | 0.02 | 1.01% | 0.17 | $99.05 | $205.00 +106.97% | $99.05 | +0.17 | 0.25 | +$0.02B+106.97% | New |
| 11 | YATSEN HLDG LTD SPONSORED ADSYSG | 0.02 | 0.90% | 4.89 - | $3.08 | - | $2.11 | 0.00 | 2.25 | +$0.00B+45.97% | Held |
| 12 | NOVABRIDGE BIOSCIENCESNBP | 0.01 | 0.88% | 5.98 - | $2.46 | - | $50.06 | 0.00 | 5.75 | -$0.28B-95.09% | Held |
| 13 | Maze Therapeutics, Inc.MAZE | 0.01 | 0.65% | 0.37 -20.00% | $29.85 | $27.81 -6.83% | $11.01 | -0.09 | 1.25 | +$0.01B+152.59% | Reduced |
| 14 | Contineum Therapeutics, Inc.CTNM | 0.01 | 0.52% | 0.67 - | $13.06 | $11.70 -10.41% | $17.61 | 0.00 | 2.00 | -$0.00B-33.56% | Held |
| 15 | Agora, Inc.API | 0.01 | 0.44% | 2.10 - | $3.54 | $3.48 -1.69% | $4.16 | 0.00 | 1.50 | -$0.00B-16.35% | Held |
| 16 | WEBULL CORPBULL | 0.01 | 0.43% | 1.50 -74.89% | $4.80 | $11.01 +129.38% | $11.96 | -4.47 | 1.00 | -$0.00B-7.94% | Reduced |
| 17 | TAIWAN SEMICONDUCTOR MFG LTDTSM | 0.01 | 0.31% | 0.02 +37.35% | $337.95 | $439.48 +30.04% | $313.15 | +0.00 | 0.50 | +$0.00B+40.34% | Increased |
| 18 | Sagimet Biosciences Inc.SGMT | 0.00 | 0.23% | 0.72 - | $5.22 | $7.36 +40.86% | $8.80 | 0.00 | 2.75 | -$0.00B-16.36% | Held |
| 19 | Tuya Inc.TUYA | 0.00 | 0.22% | 1.56 - | $2.31 | $2.28 -1.30% | $21.14 | 0.00 | 5.25 | -$0.03B-89.21% | Held |
| 20 | GE AerospaceGE | 0.00 | 0.17% | 0.01 - | $283.77 | $317.45 +11.87% | $273.58 | 0.00 | 2.25 | +$0.00B+16.03% | Held |
| 21 | Vipshop Holdings LimitedVIPS | 0.00 | 0.12% | 0.12 | $15.72 | $14.22 -9.54% | $15.72 | +0.12 | 0.25 | -$0.00B-9.54% | New |
| 22 | MOGU INC SPON ADSMOGU | 0.00 | 0.11% | 0.85 - | $2.23 | - | $3.52 | 0.00 | 4.25 | -$0.00B-36.64% | Held |
| 23 | Gossamer Bio, Inc.GOSS | 0.00 | 0.10% | 4.97 - | $0.33 | $2.19 +566.67% | $16.64 | 0.00 | 7.25 | -$0.07B-86.84% | Held |
| 24 | Intel CorporationINTC | 0.00 | 0.08% | 0.03 | $44.13 | $114.68 +159.87% | $44.13 | +0.03 | 0.25 | +$0.00B+159.87% | New |
| 25 | Pacific Biosciences of California, Inc.PACB | 0.00 | 0.07% | 0.92 - | $1.32 | $1.64 +24.24% | $8.35 | 0.00 | 2.75 | -$0.01B-80.36% | Held |
Showing 1-25 of 38
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Exited Holdings
Stocks no longer disclosed in the current 13F portfolio for 2026 Q1.
| 1 | ALPHABET INC CAP STK CL AGOOGL | 0.01 | 0.25 | $313.00 | $287.56 | -$0.00B-8.13% |
| 2 | ISHARES BITCOIN TRUST ETFIBIT | 0.04 | 0.25 | $49.65 | $38.42 | -$0.00B-22.62% |
| 3 | Moody's CorporationMCO | 0.00 | 2.25 | $449.99 | $436.25 | -$0.00B-3.05% |
| 4 | CENTRAIS ELET BRAS SA SPON ADS PF CL CEBR.B | 0.03 | 0.25 | $8.62 | $8.62 | $0.00B0.00% |
Showing 1-4 of 4
Exited holdings are stocks disclosed in the previous report period but no longer disclosed in the current 13F portfolio.
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis uses the same weighted cost-pool method as current holdings. Estimated exit price uses the current report period weighted report price when available, otherwise the previous report price; it does not represent the actual sale price.
Exit return shows estimated dollar return on top and percentage return below.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.